Abstract
A consistent neurochemical abnormality in Parkinson's disease (PD) is degeneration of dopaminergic neurons in substantia nigra, leading to a reduction of striatal dopamine (DA) levels. As tyrosine hydroxylase (TH) catalyses the formation ofl-DOPA, the rate-limiting step in the biosynthesis of DA, the disease can be considered as a TH-deficiency syndrome of the striatum. Similarly, some patients with hereditaryl-DOPA-responsive dystonia, a neurological disorder with clinical similarities to PD, have mutations in the TH gene and decreased TH activity and/or stability. Thus, a logical and efficient treatment strategy for PD is based on correcting or bypassing the enzyme deficiency by treatment withl-DOPA, DA agonists, inhibitors of DA metabolism, or brain grafts with cells expressing TH. A direct pathogenetic role of TH has also been suggested, as the enzyme is a source of reactive oxygen species (ROS) in vitro and a target for radical-mediated oxidative injury. Recently, it has been demonstrated thatl-DOPA is effectively oxidized by mammalian TH in vitro, possibly contributing to the cytotoxic effects of DOPA. This enzyme may therefore be involved in the pathogenesis of PD at several different levels, in addition to being a promising candidate for developing new treatments of this disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
(1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group.N. Engl. J. Med. 321, 1364–1371.
(1993) Mutations in the copper- and zinc-containing superoxide dismutase gene are associated with “Lou Gehrig's Disease”.Nutr. Rev. 51, 243–245.
(1995) Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.Arch. Neurol. 52, 237–245.
Adler C., Ghisla S., Rebrin I., Haavik J., Heizmann C. W., Blau N., Kuster T., and Curtius H. C. (1992) 7-substituted pterins in humans with suspected pterin-4a-carbinolamine dehydratase deficiency Mechanism of formation via non-enzym transformation from 6-substituted pterins.E Biochem. 208, 139–144.
Albino Teixeira A., Azevedo I., Martel F., and Wald W. (1991) Superoxide dismutase par prevents sympathetic denervation by 6-hyd dopamine.Naunyn Schmiedebergs Arch. Ph col. 344, 36–40.
Almås B., Le Bourdelles B., Flatmark T., Ma and Haavik J. (1992) Regulation of recom human tyrosine hydroxylase isozymes b cholamine binding and phosphorylation ture/activity studies and mechanistic implications.Eur. J. Biochem. 209, 249–255.
Andersson K. K., Cox D. D., Que L. Jr., Flatmark T., and Haavik J. (1988) Resonance Raman studies on the blue-green-colored bovine adrenal tyrosine 3-monooxygenase (tyrosine hydroxylase). Evidence that the feedback inhibitors adrenaline and noradrenaline are coordinated to iron.J. Biol. Chem. 263, 18,621–18,626.
Anton R., Kordower J. H., Maidment N. T., Manaster J. S., Kane D. J., Rabizadeh S., Schueller S. B., Yang J., Edwards R. H. and et al. (1994) Neural-targeted gene therapy for rodent and primate hemiparkinsonism.Exp. Neurol. 127, 207–218.
Baetge E. E. (1993) Neural stem cells for CNS transplantation.Ann. N.Y. Acad. Sci. 695, 285–291.
Bandmann O., Daniel S., Marsden C. D., Wood N. W., and Harding A. E. (1996a) The GTP-cyclohydrolase I gene in atypical parkinsonian patients: a clinico-genetic study.J. Neurol. Sci. 141, 27–32.
Bandmann O., Nygaard T. G., Surtees R., Marsden C. D., Wood N. W., and Harding A. E. (1996b) Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity.Hum. Mol. Genet. 5, 403–406.
Barden H. (1969) The histochemical relationship of neuromelanin and lipofuscin.J. Neuropathol. Exp. Neurol. 28, 419–441.
Bartholome K. (1983) Deficiency of tyrosine hydroxylase or tryptophan hydroxylase: a possible cause of two hypothetical metabolic diseases.Acta Paediatr. Scand. 72, 921–922.
Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases.Ann. Neurol. 38, 357–366.
Bencsics C., Wachtel S. R., Milstien S., Hatakeyama K., Becker J. B., and Kang U. J. (1996) Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis ofl-DOPA by primary fibroblasts.J. Neurosci. 16, 4449–4456.
Benedito E., Jimenez C. C., Perez D., Cubillana J. D., nez C. J., Meyer-zum G. A., Lozano ia B. J. (1997) Melanin formation in is catalyzed by a new tyrosine tinetically and structurally different se.Biochim. Biophys. Acta 1336, 59–72.
gan B., Anzivino M., and Hirsh J. ???? vel and major isoform of tyrosine in Drosophila is generated by alter-processing.J. Biol. Chem. 269, ??
Björklund A. (1993) Neurobiology. Better cells for brain repair.Nature 362, 414–415.
Blair J. A. and Pearson A. J. (1974) Kinetics and mechanism of autooxidation of the 2- amino-4-hydroxy-5,6,7,8-tetrahydrobiopteridines.J. Chem. Soc. Perkin. Trans. II, 80–88.
Bondy S.C. (1992) Reactive oxygen species: relation to aging and neurotoxic damage.Neurotoxicology 13, 87–100.
Bradbury M.W.B. (1997) Transport of iron in the blood-brain-cerebrospinal fluid system.J. Neurochem. 69, 443–454.
Calne D. B. and Takahashi H. (1991) The origin of idiopathic Parkinsonism, inParkinson's: How to Proceed Today in Treatment (Rinne, U. K., Nagatsu T., and Horowski R., eds.) Medicom EW, Bussum, pp. 3–9.
Cano E. and Mahadevan L. C. (1995) Parallel signal processing among mammalian MAPKs.Trends. Biochem. Sci. 20, 117–122.
Chen Y., Best J. A., Nagamoto K., and Tank A. W. (1996) Regulation of tyrosine hydroxylase gene expression by the m1 muscarinic acetylcholine receptor in rat pheochromocytoma cells.Brain Res. Mol. Brain Res. 40, 42–54.
Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders.Science 262, 689–695.
Czyzyk Krzeska M. F., Bayliss D. A., Lawson E. E., and Millhorn D. E. (1992) Regulation of tyrosine hydroxylase gene expression in the rat carotid body by hypoxia.J. Neurochem. 58, 1538–1546.
Czyzyk Krzeska M. F., Furnari B. A., Lawson E. E., and Millhorn D. E. (1994) Hypoxia increases rate of transcription and stability of tyrosine hydroxylase mRNA in pheochromocytoma (PC12) cells.J. Biol. Chem. 269, 760–764.
Czyzyk Krzeska M. F., Paulding W. R., Beresh J. E., and Kroll S. L. (1997) Post-transcriptional regulation of tyrosine hydroxylase gene expression by oxygen in PC12 cells.Kidney Int. 51, 585–590.
Dahl H. H. and Mercer J. F. (1986) Isolation and sequence of a cDNA clone which contains the complete coding region of rat phenylalanine hydroxylase. Structural homology with tyrosine hydroxylase, glucocorticoid regulation, and use of alternate polyadenylation sites.J. Biol. Chem. 261, 4148–4153.
Damier P., Hirsch E. C., Zhang P., Agid Y., and Javoy Agid F. (1993) Glutathione peroxidase, glial cells and Parkinson's disease.Neuroscience 52, 1–6.
Daubner S. C., Lauriano C., Haycock J. W., and Fitzpatrick P. F. (1992) Site-directed mutagenesis of serine 40 of rat tyrosine hydroxylase. Effects of dopamine and cAMP-dependent phosphorylation on enzyme activity.J. Biol. Chem. 267, 12639–12646.
Daubner S. C., Lohse D. L., and Fitzpatrick P. F. (1993) Expression and characterization of catalytic and regulatory domains of rat tyrosine hydroxylase.Protein Sci. 2, 1452–1460.
Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L., and Bates G. P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.Cell 90, 537–548.
De La Cruz C. P., Revilla E., Venero J. L., Ayala A., Cano J., and Machado A. (1996) Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rat.Free Radic. Biol. Med. 20, 53–61.
Degl'Innocenti F., Maurello M. T., and Marini P. (1989) A parkinsonian kindred.Ital. J. Neurol. Sci. 10, 307–310.
Dexter D. T., Carter C. J., Wells F. R., Javoy Agid F., Agid Y., Lees A., Jenner P., and Marsden C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.J. Neurochem. 52, 381–389.
Dexter D. T., Wells F. R., Agid F., Agid Y., Lees A. J., Jenner P., and Marsden C. D. (1987) Increased nigral iron content in postmortem parkinsonian brain [letter].Lancet 2, 1219–1220.
Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., and Marsden C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.J. Neurochem. 52, 1830–1836.
Døskeland A. P. and Flatmark T. (1996) Recombinant human phenylalanine hydroxylase is a substrate for the ubiquitin-conjugating enzyme system.Biochem. J. 319, 941–945.
Dumas S., Le Hir H., Bodeau Pean S., Hirsch E., Thermes C., and Mallet J. (1996) New species of human tyrosine hydroxylase mRNA are produced in variable amounts in adrenal medulla and are overexpressed in progressive supranuclear palsy.J. Neurochem. 67, 19–25.
During M. J., Naegele J. R., O'Malley K. L., and Geller A. I. (1994) Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase.Science 266, 1399–1403.
Ebadi M., Srinivasan S. K., and Baxi M. D. (1996) Oxidative stress and antioxidant therapy in Parkinson's disease.Prog. Neurobiol. 48, 1–19.
Egensperger R., Kosel S., Schnopp N. M., Mehraein P., and Graeber M. B. (1997) Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases.Neuropathol. Appl. Neurobiol. 23, 315–321.
Ehringer H. and Hornykiewicz O. (1960) Verteilung von noradrenalin und dopamin (3-hydroxytyramin) in gehirn des menchen und ihr verhalten bei erkrankungen des extrapyramidalen systems.Klin. Wochenschr. 38, 1236–1239.
Enochs W. S., Sarna T., Zecca L., Riley P. A., and Swartz H. M. (1994) The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.J. Neural Transm. Park. Dis. Dement. Sect. 7, 83–100.
Erlandsen H., Fusetti F., Martinez A., Hough E., Flatmark T., and Stevens R. C. (1997a) Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria.Nature Struct. Biol. 4, 995–1000.
Erlandsen H., Martinez A., Knappskog P. M., Haavik J., Hough E., and Flatmark T. (1997b) Crystallization and preliminary diffraction analysis of a truncated homodimer of human phenylalanine hydroxylase.FEBS Lett. 406, 171–174.
Evans P. H. (1993) Free radicals in brain metabolism and pathology.Br. Med. Bull. 49, 577–587.
Fink J. K., Barton N., Cohen W., Lovenberg W., Burns R. S., and Hallett M. (1988) Dystonia with marked diurnal variation associated with biopterin deficiency.Neurology 38, 707–711.
Fink J. K., Ravin P., Argoff C. E., Levine R. A., Brady R. O., Hallett M., and Barton N. W. (1989) Tetrahydrobiopterin administration in biopterindeficient progressive dystonia with diurnal variation.Neurology 39, 1393–1395.
Fink R. M. and Elstner E. F. (1984) Studies on the possible mechanism of inactivation of phenylalanine hydroxylase by destructive oxygen species.Z. Naturforsch. C. 39, 734–737.
Fisher K. J., Kelley W. M., Burda J. F., and Wilson J. M. (1996) A novel adenovirus-adeno- associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome.Hum. Gene Ther. 7, 2079–2087.
Fisher L. J., Jinnah H. A., Kale L. C., Higgins G. A., and Gage F. H. (1991) Survival and function of intrastriatally grafted primary fibroblasts genetically modified to producel-dopa.Neuron 6, 371–380.
Fitzpatrick P. F. (1989) The metal requirement of rat tyrosine hydroxylase.Biochem. Biophys. Res. Commun. 161, 211–215.
Fossom L. H., Sterling C. R., and Tank A. W. (1992) Regulation of tyrosine hydroxylase gene transcription rat and tyrosine hydroxylase mRNA stability by cyclic AMP and glucocorticoid.Mol. Pharmacol. 42, 898–908.
Fowler C. J., Wiberg A., Oreland L., Marcusson J., and Winblad B. (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase.J. Neural Transm. 49, 1–20.
Freese A., During M. J., Davidson B. L., Gennarelli T. A., Kaplitt M. G., Flamm E. S., and Snyder P. J. (1996) Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release.J. Clin. Endocrinol. Metab. 81, 2401–2404.
Gahn L. G. and Roskoski R. Jr. (1995) Thermal stability and CD analysis of rat tyrosine hydroxylase.Biochemistry 24, 252–256.
Gasser T., Wszolek Z. K., Trofatter J., Ozelius L., Uitti R. J., Lee C. S., Gusella J., Pfeiffer, R. F., Calne D. B., and Breakefield X. O. (1994) Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes.Ann. Neurol. 36, 387–396.
Gerlach M., Ben Shachar D., Riederer P., and Youdim M. B. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases?J. Neurochem. 63, 793–807.
Glorioso J. C., DeLuca N. A., and Fink D. J. (1995) Development and application of herpes simplex virus vectors for human gene therapy.Annu. Rev. Microbiol. 49, 675–710.
Goc A. and Stachowiak M. K. (1994) Bovine tyrosine hydroxylase gene-promoter regions involved in basal and angiotensin II-stimulated expression in nontransformed adrenal medullary cells.J. Neurochem. 62, 834–843.
Golbe L. I., Di Iorio G., Bonavita V., Miller, D. C., and Duvoisin R. C. (1990) A large kindred with autosomal dominant Parkinson's disease.Ann. Neurol. 27, 276–282.
Goldstein M. (1995) Long- and short-term regulation of tyrosine hydroxylase. InPsychopharmacology: The Fourth Generation of Progress (Bloom F. E. and Kupfer D. J., eds.), pp. 189–195. Raven Press, Ltd., New York.
Goodwill K. E., Sabatier C., Marks C., Raag R., Fitzpatrick P. F., and Stevens R. C. (1997) Crystal structure of tyrosine hydroxylase at 2.3 Å and its implications for inherited neurodegenerated diseases.Nature Struct. Biol. 4, 578–585.
Graham D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.Mol. Pharmacol. 14, 633–643.
Granholm A. C., Srivastava N., Mott J. L., Henry S., Henry M., Westphal H., Pichel J. G., Shen L., and Hoffer B. J. (1997) Morphological alterations in the peripheral and central nervous systems of mice lacking glial cell line-derived neurotrophic factor (GDNF): immunohistochemical studies.J. Neurosci. 17, 1168–1178.
Grima B., Lamouroux A., Boni C., Julien J. F., Javoy-Agid F., and Mallet J. (1987) A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics.Nature 326, 707–711.
Gutteridge J. M. (1994) Biological origin of free radicals, and mechanisms of antioxidant protection.Chem. Biol. Interact. 91, 133–140.
Haavik J. (1997) L-DOPA is a substrate for tyrosine hydroxylase.J. Neurochem. 69, 1720–1728.
Haavik J. and Flatmark T. (1987) Isolation and characterization of tetrahydropterin oxidation products generated in the tyrosine 3-monooxygenase (tyrosine hydroxylase) reaction.Eur. J. Biochem. 168, 21–26.
Haavik J., Almås B., and Flatmark T. (1997a) Generation of reactive oxygen species by tyrosine hydroxylase: a possible contribution to the degeneration of dopaminergic neurons?J. Neurochem. 68, 328–332.
Haavik J., Thomas G., Sutherland C., and Cohen P. (1997b) Activation of tyrosine hydroxylase by phosphorylation. A comparison of different protein kinases and phosphorylation sites, inChemistry and Biology of Pteridines and Folates (Pfleiderer W. and Rokos H., eds.) 11th International Symposium, Blackwell Science, Berlin pp. 509–514.
Haavik J., Le Bourdelles B., Martinez A., Flatmark T., and Mallet J. (1991) Recombinant human tyrosine hydroxylase isozymes. Reconstitution with iron and inhibitory effect of other metal ions.Eur. J. Biochem. 199, 371–378.
Haavik J., Martinez, A., and Flatmark T. (1990) pH-dependent release of catecholamines from tyrosine hydroxylase and the effect of phosphorylation of Ser-40.FEBS Lett. 262, 363–365.
Haavik J., Martinez A., Olafsdottir S., Mallet J., and Flatmark T. (1992) The incorporation of divalent metal ions into recombinant human tyrosine hydroxylase apoenzymes studied by intrinsic fluorescence and 1H-NMR spectroscopy.Eur. J. Biochem. 210, 23–31.
Han S., Eltis L. D., Timmis K. N., Muchmore S. W., and Bolin J. T. (1995) Crystal structure of the biphenyl-cleaving extradiol dioxygenase from a PCB-degrading pseudomonad.Science 270, 976–980.
Haycock J. W. (1993) Multiple signaling pathways in bovine chromaffin cells regulate tyrosine hydroxylase phosphorylation at Ser19, Ser31, and Ser40.Neurochem. Res. 18, 15–26.
He Y., Thong P. S., Lee T., Leong S. K., Shi C. Y., Wong P. T., Yuan S. Y., and Watt F. (1996) Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study.Brain Res. 735, 149–153.
Hearing V. J. and Jimenez M. (1987) Mammalian tyrosinase—the critical regulatory control point in melanocyte pigmentation.Int. J. Biochem. 19, 1141–1147.
Heintz N. and Zoghbi H. (1997) α-synuclein—a link between Parkinson and Alzheimer diseases?Nat. Genet. 16, 325–327.
Hillas P. J. and Fitzpatrick P. F. (1996) A mechanism for hydroxylation by tyrosine hydroxylase based on partitioning of substituted phenylalanines.Biochemistry 35, 6968–6975.
Hirsch E. C. (1994) Biochemistry of Parkinson's disease with special reference to the dopaminergic systems.Mol. Neurobiol. 9, 135–142.
Hirsch E. C. (1993) Does oxidative stress participate in nerve cell death in Parkinson's disease?Eur. Neurol. 33 Suppl. 1, 52–59.
Horellou P., Brundin P., Kalen P., Mallet J., and Björklund A. (1990) In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum.Neuron 5, 393–402.
Horellou P., Vigne E., Castel M. N., Barneoud P., Colin P., Perricaudet M., Delaere P., and Mallet J. (1994) Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease.Neuroreport.6, 49–53.
Hou J. G., Lin L. F., and Mytilineou C. (1996) Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium.J. Neurochem. 66, 74–82.
Hyman C., Hofer M., Barde Y. A., Juhasz M., Yancopoulos G. D. Squinto S. P. and Lindsay R. M. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.Nature 350, 230–232.
Ichinose H., Ohye T., Takahashi E., Seki N., Hori T., Segawa M., Nomura Y., Endo K., Tanaka H., Tsuji S., and et al (1994) Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene.Nat. Genet. 8, 236–242.
Ikebe S., Tanaka M., Ohno K., Sato W., Hattori K., Kondo T., Mizuno Y., and Ozawa T. (1990) Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence.Biochem. Biophys. Res. Commun. 170, 1044–1048.
Ischiropoulos H., Duran D., and Horwitz J. (1995) Peroxynitrite-mediated inhibition of DOPA synthesis in PC12 cells.J. Neurochem. 65, 2366–2372.
Ishida A., Yamashiro K., Mukawa J., and Hasegawa M. (1996) Regulation ofl-DOPA production by genetically modified primary fibroblasts transfected with retrovirus vector system.Cell Transplant. 5, S5-S7.
Jenner P. (1991) Oxidative stress as a cause of Parkinson's disease.Acta Neurol. Scand. Suppl. 136, 6–15.
Jenner P. and Olanow C. W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease.Neurology 47, S161–170.
Kapatos G., Hirayama K., and Stegenga S. (1997) Clinical relevance and molecular mechanisms of heterogenety in tetrahydrobiopterin biosynthesis within monoaminergic neurons.Pteridines 8, 64.
Kaplitt M. G., Leone P., Samulski R. J., Xiao X., Pfaff D. W., O'Malley K. L., and During M. J. (1994) Long-term gene expression and phenotypic correction using adeno- associated virus vectors in the mammalian brain.Nat. Genet. 8, 148–154.
Kappock T. J. and Caradonna J. P. (1996) Pterindependent amino acid hydroxylases.Chem. Rev 96, 2659–2756.
Kaufman S. (1995) Tyrosine hydroxylase.Adv. Enzymol. Relat. Areas. Mol. Biol. 70, 103–220.
Kehrer J. P. (1993) Free radicals as mediators of tissue injury and disease.Crit. Rev. Toxicol. 23, 21–48.
Kim K. S., Park D. H., Wessel T. C., Song B., Wagner J. A., and Joh T. H. (1993) A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression.Proc. Natl. Acad. Sci. USA. 90, 3471–3475.
Knappskog P. M., Flatmark T., Mallet J., Lüdecke B., and Bartholome K. (1995) Recessively inheritedl-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene.Hum. Mol. Genet. 4, 1209–1212.
Kobayashi K., Morita S., Sawada H., Mizuguchi T., Yamada K., Nagatsu I., Hata T., Watanabe Y., Fujita K., and Nagatsu T. (1995) Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice.J. Biol. Chem. 270, 27,235–27,243.
Kosel S., Egensperger R., Schnopp N. M., and Graeber M. B. (1997) The ‘common deletion’ is not increased in parkinsonian substantia nigra as shown by competitive polymerase chain reaction.Mov. Disord. 12, 639–645.
Kumer S. C. and Vrana K. E. (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression.J. Neurochem. 67, 443–462.
Kummer J. L., Rao P. K., and Heidenreich K. A. (1997) Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase.J. Biol. Chem. 272, 20,490–20,494.
Kupke K. G., Graeber M. B., and Muller U. (1992) Dystonia-parkinsonism syndrome (XDP) locus: flanking markers in Xq12-q21.1..Am. J. Hum. Genet. 50, 808–815.
Kyriakis J. M. and Avruch J. (1996) Protein kinase cascades activated by stress and inflammatory cytokines.Bioessays 18, 567–577.
Laniece P., Le-Hir H., Bodeau-Pean S., Charon Y., Valentin L., Thermes C., Mallet, J., and Dumas S. (1996) A novel rat tyrosine hydroxylase mRNA species generated by alternative splicing.J. Neurochem. 66, 1819–1825.
Levivier M., Przedborski S., Bencsics C., and Kang U. J. (1995) Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.J. Neurosci. 15, 7810–7820.
Lewis D. A., Melchitzky D. S., and Haycock J. W. (1993) Four isoforms of tyrosine hydroxylase are expressed in human brain.Neuroscience 54, 477–492.
Linert W., Herlinger E., Jameson R. F., Kienzl E., Jellinger K., and Youdim M. B. (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen—their mutual interactions and possible implication in the development of Parkinson's disease.Biochim. Biophys. Acta 1316, 160–168.
Lüdecke B., Dworniczak B., and Bartholome K. (1995) A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome.Hum. Genet. 95, 123–125.
Lüdecke B., Knappskog P. M., Clayton P. T., Surtees R. A. Clelland J. D., Heales S. J., Brand M. P., Bartholome K., and Flatmark T. (1996) Recessively inheritedl-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene.Hum. Mol. Genet. 5, 1023–1028.
Lundberg C., Horellou P., Mallet J., and Björklund A. (1996) Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model.Exp. Neurol. 139, 39–53.
Mallet J. (1996) The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders.Trends. Pharmacol. Sci. 17, 129–135.
Mann V. M., Cooper J. M., and Schapira A. H. (1992) Quantitation of a mitochondrial DNA deletion in Parkinson's disease.FEBS Lett. 299, 218–222.
Martinez A., Abeygunawardana C., Haavik J., Flatmark T., and Mildvan A. S. (1993) Conformation and interaction of phenylalanine with the divalent cation at the active site of human recombinant tyrosine hydroxylase as determined by proton NMR.Biochemistry 32, 6381–6390.
McRitchie D. A., Cartwright H. R., and Halliday G. M. (1997) Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.Exp. Neurol. 144, 202–213.
Mecocci P., MacGarvey U., Kaufman A. E., Koontz D., Shoffner J. M., Wallace D. C., and Beal M. F. (1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain.Ann. Neurol. 34, 609–616.
Mendez I., Sadi D., and Hong M. (1996) Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants.J. Neurosci. 16, 7216–7227.
Meyer Klaucke W., Winkler H., Schunemann V., Trautwein A. X., Nolting H. F., and Haavik J. (1996) Mossbauer, electron-paramagnetic-resonance and X-ray-absorption fine-structure studies of the iron environment in recombinant human tyrosine hydroxylase.Eur. J. Biochem. 241, 432–439.
Michaud Soret I., Andersson K. K., Que L. Jr., and Haavik J. (1995) Resonance Raman studies of catecholate and phenolate complexes of recombinant human tyrosine hydroxylase.Biochemistry 34, 5504–5510.
Miller N. and Vile R. (1995) Targeted vectors for gene therapy.FASEB J. 9, 190–199.
Miranda M., Botti D., and Di Cola M. (1984) Possible genotoxicity of melanin synthesis intermedia-ates: tyrosinase reaction products interact with DNA in vitro.Mol. Gen. Genet. 193, 395–399.
Moffat M., Harmon S., Haycock J., and O'Malley K. L. (1997)l-Dopa and dopamine-producing gene cassettes for gene therapy approaches to Parkinson's disease.Exp. Neurol. 144, 69–73.
Mogi M., Harada M., Kiuchi K., Kojima K., Kondo T., Narabayashi H., Rausch D., Riederer P., Jellinger K., and Nagatsu T. (1988) Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain.J. Neural Transm. 72, 77–82.
Moore M. W., Klein R. D., Farinas I., Sauer H., Armanini M., Phillips H., Reichardt L. F., Ryan A. M., Carver Moore K., and Rosenthal A. (1996) Renal and neuronal abnormalities in mice lacking GDNF.Nature 382, 76–79.
Nagatsu T. (1995) Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology.Essays. Biochem. 30, 15–35.
Nagatsu T., Levitt M., and Udenfriend S. (1964) Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis.J. Biol. Chem. 239, 2910–2917.
Nakao N., Frodl E. M., Duan W. M., Widner H., and Brundin P. (1994) Lazaroids improve the survival of grafted rat embryonic dopamine neurons.Proc. Natl. Acad. Sci. USA 91, 12,408–12,412.
Nygaard T. G., Marsden C. D., and Duvoisin R. C. (1988) Dopa-responsive dystonia.Adv. Neurol. 50, 377–384.
Okun M. R., Patel R. P., Donnellan B., Lever W. F., Edelstein L. M., and Epstein D. (1971) DOPA compared with dihydroxyfumarate as co-factor in peroxidase-mediated oxidation of tyrosine to melanin. Histochemical studies with neutrophils, eosinophils, mast cells, melanoma cells and neurons.Histochemie. 27, 331–334.
Okuno S. and Fujisawa H. (1991) Conversion of tyrosine hydroxylase to stable and inactive form by the end products.J. Neurochem. 57, 53–60.
Olanow C. W., Kordower J. H., and Freeman T. B. (1996) Fetal nigral transplantation as a therapy for Parkinson's disease.Trends. Neurosci. 19, 102–109.
Oreland L. (1991) Monoamine oxidase, dopamine and Parkinson's disease.Acta Neurol. Scand. Suppl. 136, 60–65.
Ota A., Yoshida S., and Nagatsu T. (1996) Regulation of N-terminus-deleted human tyrosine hydroxylase type 1 by end products of catecholamine biosynthetic pathway.J. Neurol. Transm. 103, 1415–1428.
Ozelius L., Kramer P. L., Moskowitz C. B., Kwiatkowski D. J., Brin M. F., Bressman S. B., Schuback D. E., Falk C. T., Risch N., de Leon D., and et al (1989) Human gene for torsion dystonia located on chromosome 9q32-q34.Neuron 2, 1427–1434.
Plante Bordeneuve V., Davis M. B., Maraganore D. M., Marsden C. D., and Harding A. E. (1994) Tyrosine hydroxylase polymorphism in familial and sporadic Parkinson's disease.Mov. Disord. 9, 337–339.
Poirier J., Kogan S., and Gauthier S. (1991) Environment genetics and idiopathic Parkinson's disease.Can. J. Neurol. Sci. 18, 70–76.
Polymeropoulos M. H., Higgins J. J., Golbe L. I., Johnson W. G., Ide S. E., Di Iorio G., Sanges G., Stenroos E. S., Pho L. T., Schaffer A. A., Lazzarini A. M., Nussbaum R. L., and Duvoisin R. C. (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23.Science 274, 1197–1199.
Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E. S., and Chandrasekharappa S. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease.Science 276, 2045–2047.
Rajput A. H., Gibb W. R., Zhong X. H., Shannak K. S., Kish S., Chang L. G., and Hornykiewicz O. (1994) Dopa-responsive dystonia: pathological and biochemical observations in a case.Ann. Neurol. 35, 396–402.
Ramsey A. J., Daubner S. C., Ehrlich J. I., and Fitzpatrick P. F. (1995) Identification of iron ligands in tyrosine hydroxylase by mutagenesis of conserved histidinyl residues.Protein Sci. 4, 2082–2086.
Ramsey A. J., Hillas P. J., and Fitzpatrick P. F. (1996) Characterization of the active site iron in tyrosine hydroxylase. Redox states of the iron.J. Biol. Chem. 271, 24,395–24,400.
Ribeiro P., Wang Y., Citron B. A., and Kaufman S. (1993) Deletion mutagenesis of rat PC12 tyrosine hydroxylase regulatory and catalytic domains.J. Mol. Neurosci. 4, 125–139.
Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K., and Youdim M. B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains.J. Neurochem. 52, 515–520.
Rodgers A. D. and Curzon G. (1975) Melanin formation by human brain in vitro.J. Neurochem. 24, 1123–1129.
Rodriguez G. J., Venero J. L., Vizuete M. L., Cano J., and Machado A. (1997) Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system.Brain Res. Mol. Brain Res. 46, 31–38.
Rosenblad C., Martinez Serrano A., and Björklund A. (1996) Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts.Neuroscience 75, 979–985.
Sanchez M. P., Silos Santiago I., Frisen J., He B., Lira S. A., and Barbacid M. (1996) Renal agenesis and the absence of enteric neurons in mice lacking GDNF.Nature 382, 70–73.
Sandri G., Panfili E., and Ernster L. (1990) Hydrogen peroxide production by monoamine oxidase in isolated rat-brain mitochondria: its effect on glutathione levels and Ca2+ efflux.Biochim. Biophys. Acta 1035, 300–305.
Schapira A. H. and Cooper J. M. (1992) Mitochondrial function in neurodegeneration and ageing.Mutat. Res. 275, 133–143.
Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G. P., Davies S. W., Lehrach H. and Wanker E. E. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.Cell 90, 549–558.
Schnopp N. M., Kosel S., Egensperger R., and Graeber M. B. (1996) Regional heterogeneity of mtDNA heteroplasmy in parkinsonian brain.Clin. Neuropathol. 15, 348–352.
Scriver C. R., Byck S., Prevost L., and Hoang L. (1996) The phenylalanine hydroxylase locus: a marker for the history of phenylketonuria and human genetic diversity. PAH Mutation Analysis Consortium.Ciba. Found. Symp. 197, 73–90.
Segawa M. (1996) [Segawa disease (hereditary progressive dystonia with marked diurnal fluctuation-HPD) and abnormalities in pteridin metabolism].Rinsho. Shinkeigaku. 36, 1322–1323.
Shults C. W., Kimber T., and Altar C. A. (1995) BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine.Neuroreport. 6, 1109–1112.
Slack R. S. and Miller F. D. (1996) Viral vectors for modulating gene expression in neurons.Curr. Opin. Neurobiol. 6, 576–583.
Smyth C., Kalsi G., Curtis D., Brynjolfsson J., O'Neill J., Rifkin L., Moloney E., Murphy P., Petursson H., and Gurling H. (1997) Two-locus admixture linkage analysis of bipolar and unipolar affective disorder supports the presence of susceptibility loci on chromosomes 11p15 and 21q22.Genomics 39, 271–278.
Snyder E. Y., Park K. I., Flax J. D., Liu S., Rosario C. M., Yandava B. D., and Aurora S. (1997) Potential of neural “stem-like” cells for gene therapy and repair of the degenerating central nervous system.Adv. Neurol. 72, 121–132.
Sofic E., Paulus W., Jellinger K., Riederer P., and Youdim M. B. (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains.J. Neurochem. 56, 978–982.
Soong N. W., Hinton D. R., Cortopassi G., and Arnheim N. (1992) Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain.Nat. Genet. 2, 318–323.
Sparks D. L., Woeltz V. M., and Markesbery W. R. (1991) Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease.Arch. Neurol. 48, 718–721.
Stachowiak M. K., Goc A., Hong J. S., Poisner A., Jiang H. K., and Stachowiak E. K. (1994) Regulation of tyrosine hydroxylase gene expression in depolarized non-transformed bovine adrenal medullary cells: second messenger systems and promoter mechanisms.Brain Res. Mol. Brain Res. 22, 309–319.
Strange P. G. (1992) Parkinson's disease. InBrain Biochemistry and Brain Disorders (Strange P. G., ed.) Oxford University Press, New York, pp 161–185.
Sutherland C., Alterio J., Campbell D. G., Le-Bourdelles B., Mallet J., Haavik J., and Cohen P. (1993) Phosphorylation and activation of human tyrosine hydroxylase in vitro by mitogen-activated protein (MAP) kinase and MAP-kinase-activated kinases 1 and 2.Eur. J. Biochem. 217, 715–722.
Thibaut F., Ribeyre J. M., Dourmap N., Meloni R., Laurent C., Campion D., Ménard J. F., Dollfus S., Mallet J., and Petit M. (1997) Association of DNA polymorphism in the first intron of the tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia.Schizophrenia. Res. 23, 259–264.
Thomas G., Haavik J., and Cohen P. (1997) Participation of a stress-activated MAP kinase cascade in the activation of tyrosine hydroxylase in chromaffin cells.Eur. J. Biochem. 247, 1180–1189.
Thöny B. and Blau N. (1997) Mutations in the GTP cyclohydrolase I and 6-pyruvoyl- tetrahydropterin synthase genes.Hum. Mutat. 10, 11–20.
Tsukahara T., Takeda M., Shimohama S., Ohara O., and Hashimoto N. (1995) Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.Neurosurgery 37, 733–739.
Tumer N., Brown J. W., Carballeira A., and Fishman L. M. (1996) Tyrosine hydroxylase gene expression in varying forms of human pheochromocytoma.Life Sci. 59, 1659–1665.
Vieregge P. (1994) Genetic factors in the etiology of idiopathic Parkinson's disease.J. Neural. Transm. Park. Dis. Dement. Sect. 8, 1–37.
Walker S. J., Liu X., Roskoski R., and Vrana K. E. (1994) Catalytic core of rat tyrosine hydroxylase: terminal deletion analysis of bacterially expressed enzyme.Biochim. Biophys. Acta 1206, 113–119.
Walkinshaw G. and Waters C. M. (1995) Induction of apoptosis in catecholaminergic PC12 cells byl-DOPA. Implications for the treatment of Parkinson's disease.J. Clin. Invest. 95, 2458–2464.
Wang Y., Tien L. T., Lapchak P. A., and Hoffer B. J. (1996) GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats.Cell Tissue Res. 286, 225–233.
Warner H. R. (1994) Superoxide dismutase, aging, and degenerative disease.Free Radic. Biol. Med. 17, 249–258.
Whittemore E. R., Loo D. T., and Cotman C. W. (1994) Exposure to hydrogen peroxide induces cell death via apoptosis in cultured rat cortical neurons.Neuroreport. 5, 1485–1488.
Wijker M., Wszolek Z. K., Wolters E. C., Rooimans M. A., Pals G., Pfeiffer R. F., Lynch T., Rodnitzky R. L., Wilhelmsen K. C. and Arwert F. (1996) Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21.Hum. Mol. Genet. 5, 151–154.
Wolff J. A., Fisher L. J., Xu L., Jinnah H. A., Langlais P. J., Iuvone P. M., O'Malley K. L., Rosenberg M. B., Shimohama S., Friedmann T., and et al. (1989) Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.Proc. Natl. Acad. Sci. USA 86, 9011–9014.
Woodgett J. R., Avruch J., and Kyriakis J. (1996) The stress activated protein kinase pathway.Cancer Surv. 27, 127–138.
Wu D. K. and Cepko C. L. (1994) The stability of endogenous tyrosine hydroxylase protein in PC-12 cells differs from that expressed in mouse fibroblasts by gene transfer.J. Neurochem. 62, 863–872.
Wu J., Filer D., Friedhoff A. J., and Goldstein M. (1992) Site-directed mutagenesis of tyrosine hydroxylase. Role of serine 40 in catalysis.J. Biol. Chem. 267, 25754–25758.
Wu R. M., Murphy D. L., and Chiueh C. C. (1996) Suppression of hydroxyl radical formation and protection of nigral neurons by 1-deprenyl (selegiline).Ann. NY Acad. Sci. 786, 379–390.
Yoshimoto Y., Lin Q., Collier T. J., Frim D. M., Breakefield X. O., and Bohn M. C. (1995) Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease.Brain Res. 691, 25–36.
Youdim M. B. and Riederer P. (1997) Understanding Parkinson's disease.Sci. Am. 276, 52–59.
Yurek D. M., Lu W., Hipkens S., and Wiegand S. J. (1996) BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons.Exp. Neurol. 137, 105–118.
Zhou Q. Y., Quaife C. J., and Palmiter R. D. (1995) Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development.Nature 374, 640–643.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haavik, J., Toska, K. Tyrosine hydroxylase and Parkinson's disease. Mol Neurobiol 16, 285–309 (1998). https://doi.org/10.1007/BF02741387
Issue Date:
DOI: https://doi.org/10.1007/BF02741387